| scholarly article | Q13442814 |
| P50 | author | Jun Wada | Q37383314 |
| P2093 | author name string | Hirofumi Makino | |
| Yutaka Oiso | |||
| Daisuke Koya | |||
| Daisuke Ogawa | |||
| Hisazumi Araki | |||
| Takashi Uzu | |||
| Masahiko Ando | |||
| Akira Nishiyama | |||
| Hiroyuki Kobori | |||
| Seiichi Matsuo | |||
| Keizo Kanasaki | |||
| Enyu Imai | |||
| Shoichi Maruyama | |||
| Sawako Kato | |||
| Motomitsu Goto | |||
| P2860 | cites work | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | Q24657470 |
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Global and societal implications of the diabetes epidemic | Q29614551 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. | Q33714897 | ||
| Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy | Q35179398 | ||
| Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats | Q36026810 | ||
| Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications | Q36033383 | ||
| Urinary neutrophil gelatinase-associated lipocalin levels in comparison with glomerular filtration rate for evaluation of renal function in patients with diabetic chronic kidney disease | Q36191746 | ||
| Predictors of diabetic end-stage renal disease in Japan | Q36262390 | ||
| Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 | ||
| Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions | Q37333543 | ||
| The renal tubulointerstitium in diabetes mellitus | Q37771593 | ||
| Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. | Q38169395 | ||
| Revised equations for estimated GFR from serum creatinine in Japan | Q39513402 | ||
| Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease | Q39912709 | ||
| Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress | Q43548036 | ||
| Overview of regular dialysis treatment in Japan (as of 31 December 2009). | Q43610757 | ||
| Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease | Q43743641 | ||
| Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. | Q44245147 | ||
| Effectiveness of aldosterone blockade in patients with diabetic nephropathy | Q44269017 | ||
| Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats | Q45085855 | ||
| Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. | Q45943305 | ||
| Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? | Q46418538 | ||
| Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (IN | Q46479723 | ||
| Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study | Q46670272 | ||
| Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl | Q46687656 | ||
| Beneficial impact of spironolactone in diabetic nephropathy | Q46826573 | ||
| Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus | Q46874844 | ||
| GFR estimation using standardized serum cystatin C in Japan | Q47264246 | ||
| Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes | Q50800640 | ||
| Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study | Q51026854 | ||
| Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease | Q79226809 | ||
| Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function | Q79279587 | ||
| Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis | Q79529985 | ||
| Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes | Q80049813 | ||
| P433 | issue | 6 | |
| P921 | main subject | diabetic nephropathy | Q1129105 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1098-1106 | |
| P577 | publication date | 2015-03-21 | |
| P1433 | published in | Clinical and experimental nephrology | Q26842022 |
| P1476 | title | Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial | |
| P478 | volume | 19 |
| Q64070851 | Aldosterone Antagonists Reduce the Risk of Cardiovascular Mortality in Dialysis Patients: A Meta-Analysis |
| Q37566950 | Blood pressure control in type 2 diabetic patients |
| Q91142607 | Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice |
| Q88727557 | Effects of RAAS Inhibitors in Patients with Kidney Disease |
| Q40965113 | Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy |
| Q93025188 | Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study |
| Q38734501 | Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q36948557 | Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study). |
| Q101578601 | Role of mineralocorticoid receptor antagonists in kidney diseases |
| Q64228363 | Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes |
| Q93169634 | The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy |
| Q36297539 | Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy |
| Q47781932 | Urinary peptidomics in kidney disease and drug research |
Search more.